|Articles|February 1, 2004

Filler era offers new options, challenges

Waikoloa, Hawaii - The U.S. Food and Drug Administration's recent approval of the cosmetic dermal filler Restylane (Medicis) indicates the beginning of a new phase for dermatologists due to the enhanced benefits it offers patients, according to Mark G. Rubin, M.D.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME